ABSTRACT
The aim of this study was to systematically review the efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in patients with advanced lung cancer. PubMed, MEDLINE, EBSCO, FMJS and Web of Science were searched to obtain randomized controlled trials [RCTs], published in English and Chinese, until February 2016. The evaluating indicators were complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD], overall response rate [ORR], disease control rate [DCR], one-year overall survival, two-year overall survival and adverse events. Revman 5.2 software was used for data syntheses and analyses. A total of 296 patients enrolled in 5 RCTs were ultimately included in this study based on our selection criteria, and 150 patients received chemotherapy alone, while another 146 patients received the combination therapy of iodine-125 brachytherapy and chemotherapy. The results showed that iodine-125 brachytherapy combined with chemotherapy was superior to chemotherapy alone in CR [risk ratio [RR] = 3.66, 95% confidence interval [CI]: 2.08 to 6.44, p<0.001], PR [RR = 1.47, 95% CI: 1.16 to 1.86, p=0.001], ORR [RR = 1.85, 95% CI: 1.54 to 2.22, p<0.001], DCR [RR = 1.19, 95% CI: 1.10 to 1.29, p<0.001], one-year overall survival [RR = 1.46, 95% CI: 1.12 to 1.92, p=0.006] and PD [RR = 0.20, 95% CI: 0.09 to 0.43, p<0.001]; meanwhile, there was no significant difference in two-year overall survival [RR = 1.30, 95% CI: 0.72 to 2.37, p=0.39]. In terms of adverse events, the combination therapy significantly increased the incidence of pneumothorax [RR = 4.93, 95% CI: 1.94 to 12.55, p=<0.001]; however, no significant differences were found in the incidence of other adverse events. This study indicated that the combination therapy of iodine-125 brachytherapy and chemotherapy could improve the therapeutic efficacy of advanced lung cancer without increasing the incidence of adverse events, except pneumothorax
Subject(s)
Humans , Brachytherapy , Iodine Radioisotopes , Treatment Outcome , Safety , Antineoplastic Agents , Review Literature as Topic , Randomized Controlled Trials as TopicABSTRACT
Background and purpose: Peroxiredoxin Ⅱ (PrxⅡ) has the activity of peroxidase. The relevant studies found it played an important role in gastric cancer. This study aimed to investigate the expression of PrxⅡ in human gastric cancer tissues and cells, analyze its relationship with clinicopathological characteristics, and explore the relationship between PrxⅡ and the prognosis and the development of gastric cancer. Methods: The expression of PrxⅡmRNA and protein in gastric cancer tissues and the paired adjacent normal tissues from 45 patients was detected by real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) and Western blot. The same methods were used to detect the expression of PrxⅡ mRNA and protein in GES-1, MGC-803, MKN-45 and MKN-28. Tissue mi-croarray and immunohistochemistry were used to detect the expression of PrxⅡ protein in gastric cancer tissues and the paired adjacent normal tissues from 116 patients. The relationship between the results and clinicopathological char-acteristics was analyzed. The prognosis was analyzed. Results: According to results of RTFQ-PCR and Western blot, we found that PrxⅡ mRNA and protein in gastric cancer tissues were significantly higher than that in adjacent normal tissues (P<0.05). PrxⅡ mRNA and protein in gastric cancer cells were higher than that in normal gastric cells (P<0.01).Immunohistochemistry revealed that the expression of PrxⅡ protein in gastric cancer tissues (76.7％) was also significantly higher (P<0.01) than that in adjacent normal tissues (30.1％). The expression of PrxⅡ protein is significantly related to tumor size, histological differentiation, depth of invasion, TNM stage and lymph node metastasis (P<0.05), but had no significant relationship with the gender, age, tumor location and distant metastasis. Survival in patients with higher PrxⅡ expression significantly shorter than in those with lower expression (P<0.01). PrxⅡ is an independent prognostic factor of gastric cancer (P<0.05). Conclusion: PrxⅡ promotes the development of gastric cancer. It is one of the adverse prognostic factors of gastric cancer and may serve as a new therapeutic target for gastric cancer.